Skip to Main Content

Paper Details

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Blood Adv
18
2023
Author NameAffiliation
Mauno VihinenLund University
Svitlana TyekuchevaDana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University
Gordon SaksenaBroad Institute of Massachusetts Institute of Technology and Harvard
Gordon SaksenaBroad Institute of Massachusetts Institute of Technology and Harvard
Kahn Rhrissorrakrai
Ignaty LeshchinerBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzHarvard Medical School
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard
Gad GetzHarvard Medical School
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital
  • 1 - 12

Datasets